A novel FRET-based screen in high-throughput format to identify inhibitors of malarial and human glucose transporters by Kraft, Thomas E et al.
Washington University School of Medicine
Digital Commons@Becker
Open Access Publications
2016
A novel FRET-based screen in high-throughput
format to identify inhibitors of malarial and human
glucose transporters
Thomas E. Kraft
Washington University School of Medicine in St. Louis
Monique R. Heitmeier
Washington University School of Medicine in St. Louis
Marina Putanko
Washington University School of Medicine in St. Louis
Rachel L. Edwards
Washington University School of Medicine in St. Louis
Ma Xenia G. Ilagan
Washington University School of Medicine in St. Louis
See next page for additional authors
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Kraft, Thomas E.; Heitmeier, Monique R.; Putanko, Marina; Edwards, Rachel L.; Ilagan, Ma Xenia G.; Payne, Maria A.; Autry, Joseph
M.; Thomas, David D.; Odom, Audrey R.; and Hruz, Paul W., ,"A novel FRET-based screen in high-throughput format to identify
inhibitors of malarial and human glucose transporters." Antimicrobial agents and chemotherapy.60,12. 7407-7414. (2016).
https://digitalcommons.wustl.edu/open_access_pubs/5378
Authors
Thomas E. Kraft, Monique R. Heitmeier, Marina Putanko, Rachel L. Edwards, Ma Xenia G. Ilagan, Maria A.
Payne, Joseph M. Autry, David D. Thomas, Audrey R. Odom, and Paul W. Hruz
This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/open_access_pubs/5378
A Novel Fluorescence Resonance Energy Transfer-Based Screen in
High-Throughput Format To Identify Inhibitors of Malarial and
Human Glucose Transporters
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The glucose transporter PfHT is essential to the survival of the malaria parasite Plasmodium falciparum and has been shown to
be a druggable target with high potential for pharmacological intervention. Identification of compounds against novel drug tar-
gets is crucial to combating resistance against current therapeutics. Here, we describe the development of a cell-based assay sys-
tem readily adaptable to high-throughput screening that directly measures compound effects on PfHT-mediated glucose trans-
port. Intracellular glucose concentrations are detected using a genetically encoded fluorescence resonance energy transfer
(FRET)-based glucose sensor. This allows assessment of the ability of small molecules to inhibit glucose uptake with high accu-
racy (Z= factor of>0.8), thereby eliminating the need for radiolabeled substrates. Furthermore, we have adapted this assay to
counterscreen PfHT hits against the human orthologues GLUT1, -2, -3, and -4. We report the identification of several hits after
screening theMedicines for Malaria Venture (MMV)Malaria Box, a library of 400 compounds known to inhibit erythrocytic
development of P. falciparum. Hit compounds were characterized by determining the half-maximal inhibitory concentration
(IC50) for the uptake of radiolabeled glucose into isolated P. falciparum parasites. One of our hits, compoundMMV009085,
shows high potency and orthologue selectivity, thereby successfully validating our assay for antimalarial screening.
Malaria is a major threat to the human population in largeareas of the world, affecting over 200million people per year
(1, 2). Beyond the effects of this disease onhuman life,malaria also
cripples economic development and burdens the health care sys-
tems of countries wheremalaria is endemic (3). The emergence of
parasites with resistance to even the most potent existing antima-
larial drugs, such as the artemisinins (4), hasmade paramount the
development of novel drugs that target essential pathways for par-
asite survival. Blood stage parasites utilize glucose for both bio-
mass production and ATP synthesis (5). The malarial hexose
transporter, Plasmodium falciparum hexose transporter (PfHT),
first cloned byWoodrow et al. in 1999 (6),mediates parasite trans-
port of glucose, fructose, mannose, and galactose (7). Since PfHT
is essential for parasite survival (8), this protein is a highly prom-
ising molecular target for antimalarial drug development. This is
supported by the ability of compound 3361, a glucose analogue
that inhibits PfHT with high selectivity over the human ortho-
logue GLUT1, to inhibit asexual intraerythrocytic growth in cul-
ture (9). Compound 3361 is also active against Plasmodium ber-
ghei liver and transmission stage parasites in infected mice (10),
suggesting that PfHT is a promising target for full life cycle activ-
ity. However, while compound 3361 validates efforts to target
PfHT, this compound is not itself considered drug-like and is
therefore not a valid candidate for lead development (11). We
have recently extended these earlier findings by identifying PfHT
as a molecular target of the HIV protease inhibitor lopinavir, thus
providing a link between lopinavir use and decreased malarial
transmission in areas where HIV and malaria are both endemic
(12). However, lopinavir has a relatively high half-maximal inhib-
itory concentration (IC50), 16 M, in parasites and shows higher
selectivity for the human insulin-responsive glucose transporter
GLUT4 over PfHT (12). Therefore, novel therapeutics targeting
PfHT with improved potency and selectivity are required.
The development of a robust and efficient high-throughput
screening assay to identify novel PfHT inhibitors requires consid-
eration of simplicity, sensitivity, scalability, cost, and reliability.
Current assays for transporter inhibition in a high-throughput
format generally employ radiolabeled substrate or cell death of a
transporter-overexpressing cell line as a readout (13, 14). Both
formats have significant limitations. Although measuring the up-
take of radiolabeled substrate generally yields quantitative, highly
reproducible results, the use and disposal of radiolabels are expen-
sive and handling radioactive substances requires increased safety
precautions. Alternatively, using cell death of an engineered cell
line that requires transporter function for survival is an elegant
way to simplify the readout. In both cases, these assays fail to
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discriminate between compounds that kill the cells through trans-
porter inhibition and compounds that kill through other mecha-
nisms, resulting in false-positive rates as high as 97.8% (15). Here,
we report the development and validation of a novel assay for
determination of compounds that efficiently and selectively block
PfHT.
MATERIALS AND METHODS
Materials. [14C]2-deoxyglucose (2-DOG) and [3H]2-DOG were pur-
chased from American Radiolabels Inc. GLUT1 short hairpin RNA
(shRNA) was obtained through the RNA interference (RNAi) core at
Washington University School of Medicine. HEK293 cells were acquired
from the American Type Culture Collection (ATCC). Lopinavir was ob-
tained through the NIH AIDS Reagent Program, Division of AIDS,
NIAID, NIH.
HEK293 cell line generation. HEK293 cells were transfected with
pcDNA3.1 FLII12Pglu-7006 (Addgene), containing the fluorescence
resonance energy transfer (FRET) glucose sensor (HEK293-FLIP), using
Optifect reagent (Life Technologies) according to the manufacturer’s
specifications. Cells that stably integrated the gene were selected using
G418 (Sigma-Aldrich), and the highest expressers were identified using
fluorescence-activated cell sorting (FACS). These cells were then stably
transfectedwith PfHT, humanGLUT1 (hGLUT1), hGLUT2, hGLUT3, or
hGLUT4 DNA in the pcDNA 3.1() hygro plasmid (Life Technologies)
as described previously (12). Single clones were selected by comparing
their abilities to transport radiolabeled glucose. In all cell lines except for
HEK293 cells overexpressing hGLUT1, native hGLUT1 was knocked
down using shRNA as described elsewhere (12). PfHT expression levels in
overexpressing cells were previously characterized (12).
RNA isolation and qPCR. To quantify mRNA transcript levels in the
four GLUT-overexpressing cell lines, total RNA was isolated using the
TrizolWPlus RNApurification system (Invitrogen), and 1g of RNAwas
reverse transcribed using qScript cDNA Supermix (Quanta Biosciences).
Quantitative reverse transcription-PCR (qRT-PCR) was performed using
Power SYBR green PCR master mix (Applied Biosystems). Each reaction
was run in triplicate using the primers listed in Table 1. Quantifications
were performed with standard curves generated using plasmids contain-
ing each human GLUT (DNASU).
Assay optimization and high-throughput screening. Several condi-
tions were optimized to increase the sensitivity and reliability of the assay.
Ninety-six-well plates were pretreated with 25g/ml of polyethylenimine
(PEI; 750 kDa; Sigma-Aldrich) solution containing 150 mM NaCl to
maintain cell adhesion during washing steps. After 20 min of incubation
at room temperature, PEI was aspirated andwells were air dried for 5min.
PfHT-FLIP cells were plated 48 h prior to the assay in black opaque 96-
well plates (Greiner Bio-One), which had been previously treated with
PEI, at 30,000 cells/well. After cell plating, plates were left in the sterile
hood at room temperature for 45 min before transfer to the incubator to
reduce edge effects. Compound screening was performed using the inte-
grated and automated screening system (Beckman Coulter) at the Wash-
ington University High Throughput Screening Core. We used SAMI EX
software (BeckmanCoulter) to design and execute the screening protocol.
The Malaria Box (Medicines for Malaria Venture [MMV]) compound
library was prediluted in glucose-free HEPES-buffered saline solution
(HBSS) (146 mMNaCl, 4.7 mMKCl, 0.6 mMMgSO4, 1.6 mMNaHCO3,
0.13 mM NaH2PO4, 2.5 mM CaCl2, 20 mM HEPES [pH 7.3]) using a
BiomekFX liquid handler (Beckman Coulter). We prepared a 1:100 dilu-
tion of 1 mM stock solution for a 10 M final concentration.
To initiate the screening assay, cells were washed twice with 150 l of
HBSS per well using an ELx405 plate washer (Biotek). Cells were starved
in HBSS for 30 min at room temperature, followed by aspiration of the
HBSS from cell plates using the ELx405 plate washer. Cells were treated
with 45l of diluted compound using the BiomekFX (with 3 replicate cell
plates for each library plate) and incubated for 6 min at room tempera-
ture. To initiate the uptake, 5l of 100mMglucose was added to the wells
(final concentration, 10 mM) using a Multidrop384 dispenser (Thermo
Fisher Scientific). After incubation at room temperature for 120 min,
fluorescence was measured using a 2102 EnVision multilabel plate reader
(PerkinElmer) at an excitation wavelength of 436 nm (cyan fluorescent
protein [CFP]) and emission wavelengths of 485 nm (CFP) and 535 nm
(yellow fluorescent protein [YFP]).
P. falciparum culture. P. falciparum strain 3D7was obtained from the
Malaria Research and Reference Reagent Resource Center (MR4). P. fal-
ciparum parasites were cultured in a 2% suspension of human erythro-
cytes and RPMI 1640 medium (Sigma-Aldrich) supplemented with 27
mM sodium bicarbonate, 11 mM glucose, 5 mM HEPES, 1 mM sodium
pyruvate, 0.37 mM hypoxanthine, 0.01 mM thymidine, 10 g/ml of gen-
tamicin, and 0.5%Albumax (Gibco) at 37°C in a 5%O2–5%CO2–90%N2
atmosphere as previously described (16, 17).
P. falciparum growth inhibition assays.Asynchronous P. falciparum
cultures were diluted to 1% parasitemia and were treated with com-
pounds at concentrations ranging from 9.8 nM to 20 M. Growth inhi-
bition assays were performed in 100-l cultures in opaque 96-well plates.
Parasite growth was quantified after 3 days by measuring DNA content
using PicoGreen (Life Technologies) (18). Fluorescence was measured by
a FLUOstar Omega microplate reader (BMG Labtech) at a 485-nm exci-
tation wavelength and a 528-nm emission wavelength. IC50s were calcu-
lated by nonlinear regression analysis using GraphPad Prism software.
Measurements of radiolabeled glucose uptake. P. falciparum strain
3D7 was cultured in 100-mm tissue culture dishes (Techno Plastic Prod-
ucts) in a 2% suspension of human erythrocytes and RPMI 1640medium
until reaching 5% parasitemia. Cells were pelleted via centrifugation
and resuspended in RPMI 1640 medium. In order to determine the up-
take of radiolabeled glucose into the parasite, we isolated it from the eryth-
rocytes while removing uninfected erythrocytes as described in references
19 and 20. Uptake of [14C]2-DOG into isolated parasites was determined
TABLE 1 Human glucose transporter primers for qPCR
Target Forward primer sequence Reverse primer sequence Amplicon size (bp)
GLUT1 AACTCTTCAGCCAGGGTCCAC CACAGTGAAGATGATGAAGAC 140
GLUT2 TTTCAGGCCTGGTTCCTATG GATGGCCAGCTGATGAAAAG 86
GLUT3 ACTTTGACGGACAAGGGAAATG ACCAGTGACAGCCAACAGG 180
GLUT4 CATGCTGGTCAACAATGTCC CCAATGAGGAATCGTCCAAG 105
GLUT5 GTCGGCCCCTTGGTGAATAA AATGATGTGGCGACTCTGCT 110
GLUT6 GGCTGCTCATGTCTGAGGTC GATGGCCGCGAAGAAGAAGAA 161
GLUT7 TGCAGGCATCTCCTACAGC ACGAAAACCTCGGTCATTGTTC 96
GLUT8 CCATCTTTGAAGAGGCCAAG ATGACCACACCTGACAAGACC 145
GLUT9 TGGCAAAGATCCCATACGTC AGGTGCTCAATGACCAAACC 85
GLUT10 GCTGTCCTGCAATCCCTCAG GTCCGGCCTCGCATGTTATC 173
GLUT11 GGAGTCAATGCAGGTGTGAG CCAGAGCCGTAAAGATGGCTG 112
GLUT12 TGCTGGATTAAGCCACACTG TGGCTAAGGACAGCCATTTC 83
Kraft et al.
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at room temperature using the methods described previously (19). Test
compounds were added 5 min prior to the addition of [14C]2-DOG (0.2-
Ci/ml final concentration). Uptake was quenched after 2min. Data were
fit by nonlinear regression analysis using GraphPad Prism software. Up-
take of [3H]2-DOG into HEK293-FLIP cells was measured in HEPES-
buffered saline at room temperature for 4 min as described previously
(20). Data were fit by nonlinear regression analysis usingGraphPad Prism
software.
RESULTS
Assay development and optimization. The ideal PfHT assay
would evaluate transporter function as a direct, highly reproduc-
ible readout without the use of radiolabels. We therefore designed
a cell line that transports glucose almost exclusively through PfHT
and combined this with an intracellular glucose sensor protein
that translates glucose concentration into a fluorescence signal as
a readout.We used the glucose sensor FLII12Pglu-7006 (FLIP),
initially developed and characterized in the laboratory of Wolf
Frommer, to qualitatively assess cellular glucose influx (21). This
genetically encoded optical glucose sensor consists of three pro-
tein domains: a central glucose-binding domain that is coupled
terminally to a CFP and a YFP. Upon excitation of CFP, energy is
transferred to YFP through FRET.When glucose enters the cell, it
binds to the glucose binding domain, leading to a conformational
change that brings the two fluorescent proteins closer together
and increases FRET (Fig. 1). Using the human embryonic kidney
cell line HEK293, we created a reporter cell line stably expressing
PfHT in conjunction with FLIP (PfHT-FLIP cells). HEK293 cells
are known to exhibit relatively low endogenous glucose uptake
(21). To further reduce background levels of glucose uptake, we
knocked down the primary endogenous transporter isoform
GLUT1 using shRNA, yielding a cell line that predominantly
transports glucose through PfHT (12). We tested the function of
our engineered cell line by measuring the time course of glucose
uptake via readout of the YFP/CFP ratio (FRET ratio) in the pres-
ence and absence of knownPfHT inhibitors. In the presence of the
HIV protease inhibitor lopinavir (Fig. 2a), previously identified to
block PfHT-mediated glucose uptake, PfHT-FLIP cells showed a
decreased FRET ratio with addition of D-glucose, consistent with
inhibition of radiolabeled D-glucose uptake in these cells (12).
Additionally, we confirmed concentration-dependent inhibition
of glucose uptake in PfHT-FLIP cells by the glucose transport
inhibitor cytochalasin B (CB) as previously shown in Xenopus
laevis oocytes (6). In PfHT-FLIP cells, CB causes a maximal de-
crease in FRET ratio of 75% at 50 M, consistent with radiola-
beled uptake inhibition in oocytes (6) and complete inhibition of
D-glucose uptake at 200 M (Fig. 2b). CB is therefore an ideal
positive control for assay optimization and high-throughput
screening.
We optimized the assay for high-throughput application in a
96-well format using the Z= factor and the coefficient of variation
(CV) as measures of assay robustness (22). For these measure-
ments, half of the plate was treated with 200 M CB as a positive
control and the other half with a vehicle prior to the addition of
D-glucose. Cells adhered tightly to the plate bottom after treat-
ment of the plate with the highly branched polymer PEI, which
acted as an adhesive, thereby preventing cells fromdislodging dur-
ingwashing and buffer exchange steps. After optimization of assay
FIG 1 (a) Generation of cell lines for high-throughput screening. HEK293
cells were stably transfected with the P. falciparum hexose transporter (PfHT)
and the glucose sensor FLII1212Pglu-7006 and treated with small interfer-
ing RNA (siRNA) directed at hGLUT1 to reduce background glucose uptake.
(b) Glucose FRET sensor expressed in PfHT-expressing cells. In the absence of
glucose, CFP and YFP are further apart and the amount of energy transferred
from the donor CFP to the acceptor YFP that is emitted as light (FRET signal)
is low (figure adapted from reference 21; usedwith permission). Glucose bind-
ing to the glucose/galactose binding domain (MgIB) leads to a conformational
change that brings CFP and YFP closer together, resulting in an increased
FRET signal.
FIG 2 (a) Time-dependent change in FRET ratio (YFP emission/CFP emis-
sion) after addition of glucose to PfHT-FLIP cells in the presence or absence of
lopinavir. (b) Time-dependent change in FRET ratio after addition of glucose
to PfHT-FLIP cells in the presence or absence of cytochalasin B (CB).
Glucose Transporter FRET Screen
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temperature, fluorescence read mode, cell density, and cell
plating protocol, we were able to routinely obtain a Z= factor of
0.8 (a perfect assay would have a Z= factor of 1.0) and a CV of
2% (Fig. 3).
Screening of the Malaria Box compound library. In order to
test our assay conditions in an automated setting for high-
throughput application, we selected the MMV Malaria Box, a
small library of 400 compounds previously shown to have a cyto-
toxic effect on malaria parasites (23). This library contains chem-
ically diverse compounds, with half of the compounds having
drug-like properties and the other half having been selected as
molecular probes. As this compound set was selected for their
cytotoxic activity against blood stagemalaria parasites, themolec-
ular drug targets remain to be determined. The rationale for
choosing this library was to identify compounds that inhibit par-
asite growth mainly or partially through blockade of PfHT-medi-
ated glucose uptake, since deorphanization of these compounds
(i.e., identification of the direct molecular targets of anti-antima-
larial action) will aid in further target-directed drug development.
We screened theMalaria Box at 10Mdrug concentrations in
triplicate and selected hits that decrease the FRET ratio by more
than 30% with vehicle-treated cells set to 100% and cells treated
with 200MCB set to 0%. Since fluorescent compounds have the
potential to generate false-positive hits, the FRET ratio of com-
pounds without cells present was determined. After false-positive
elimination, we identified 5 compounds as primary hits. Hit con-
firmation was ascertained by determining the IC50 for glucose
uptake into isolated P. falciparum parasites from blood culture
using radiolabeled D-glucose. Four of the five primary hits could
be confirmed to inhibit glucose uptake into P. falciparum para-
sites in the low micromolar range (Table 2), with compound
MMV665941 showing only partial inhibition at the highest con-
centration tested (Fig. 4). We included compound MMV020548
for comparison as it was previously identified by Ortiz et al. (15)
from the same library. The similar IC50 observed in the free-par-
asite glucose uptake assay and in vitro growth inhibition assay for
MMV009085 (23) is consistent with the interpretation that this
compound acts through PfHT blockage to inhibit parasite growth
(Table 2), although alternative targets in the parasite might be
inhibited as well. Since the measurement of 2-DOG uptake in-
volves both the transport of this sugar and phosphorylation to
2-DOG-6-phosphate (2-DOG-6-P), we cannot fully exclude the
possibility that the identified compounds also inhibit the malarial
hexokinase. However, the observations that they inhibit 2-DOG
uptake with different potencies and that compoundMMV009085
shows a widely different IC50 when measured in HEK293 cells
overexpressing different GLUTs (see Fig. 6) suggest that hexoki-
nase is not directly targeted.
To establish selectivity of these hits for PfHT over human or-
thologues, we cross-validated the inhibition of GLUT1, -2, -3, and
-4 by the confirmed hits. Using the same HEK293-FLIP cell line,
we overexpressed each of the individual class I transporters. With
the exception of GLUT1-FLIP, the other GLUT cell lines were also
treated with GLUT1-specific shRNA to reduce background glu-
cose uptake. We confirmed that the overexpressed GLUT was the
main glucose transporter expressed in each cell line by comparing
the cDNA copy number of all human SLC2A genes via qPCR (Fig.
5). Total transcript numbers differed between various GLUT iso-
form-overexpressing cell lines as the construct was integrated ran-
domly into the genome of the host cell as discussed in Materials
and Methods. We determined the inhibitory effects of the five
confirmed hits on all four human class I GLUTs at the IC50 for
PfHT-mediated glucose uptake inhibition. Only compound
MMV009085, the most potent hit, with an IC50 of 2.6 M for
FIG3 FRET ratio perwell of a 96-well plate, with 48wells treatedwith 200M
CB (inhibitor) and 48 wells treated with a vehicle. Z= factor and the coefficient
of variation (CV)were determined from the average and SDof each set of wells
according to reference 20.
TABLE 2 Comparison of hit IC50s for different assays
a
Compound ID
Heterologous screening assay
(% inhibition at 10 M)
IC50 for glucose
uptake in freed
parasites
EC50 for growth
inhibition of P.
falciparum 3D7
EC50 for P. falciparum
growth inhibition,
Malaria Box
IC50 for
L. mexicana
MMV020548 21 15.5 0.114 0.361 3.5
MMV665941 31 19.6 0.026 0.255 ND
MMV009085 87 2.6 0.987 0.795 0.051
MMV000326 49 286 0.344 1.170 ND
MMV665879 49 8.3 0.390 ND 2.7
MMV665898 64 5.3 0.487 1.220 ND
a IC50s for glucose uptake in freed parasites were determined from dose-response curves shown in Fig. 4. IC50s for inhibition of growth of P. falciparum strain 3D7 intraerythrocytic
forms by each compound were determined via a growth inhibition assays as described in Materials and Methods. Half-maximal effective concentrations (EC50s) provided with the
malaria box and IC50 values determined by Ortiz et al. (15) for inhibition of glucose uptake into PfHT-overexpressing L. mexicana parasites are also tabulated. ID, identifier; ND,
not determined.
Kraft et al.
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PfHT-mediated glucose uptake, showed significantly less inhibi-
tion of the humanGLUTs than for PfHT (Fig. 6a). Comparison of
the IC50s for glucose uptake inhibition, mediated by either the
human GLUTs or PfHT, revealed a10-fold-higher selectivity of
MMV009085 for PfHT over human orthologues (Fig. 6b). Al-
thoughMMV009085 is considered a probe-like molecule, its high
potency in inhibiting both glucose uptake and growth of the par-
asites as well as its high selectivity for PfHT over human ortho-
logues makes this compound a potential candidate for lead opti-
mization. Additionally, it demonstrates that our newly developed
FIG 4 Uptake of [14C]2-DOG by isolated P. falciparum trophozoites at increasing concentrations of hit compounds. Distribution ratios (i.e., the ratio of
intracellular concentration of radiolabel relative to the extracellular concentration) were calculated as described previously (14). IC50s were calculated using
nonlinear regression analysis and are tabulated in Table 2. Uptake data are expressed asmeans SEMs (n 3). Chemical structures of the compounds tested are
shown for comparison.
FIG 5 Copies of transcript per nanogram of cDNA for each glucose transporter SLC2A familymember in HEK293-FLIP cells overexpressing (OE) hGLUT1 (a),
hGLUT2 (b), hGLUT3 (c), and hGLUT4 (d) in comparison to HEK293 wild-type cells and/or HEK293 wild-type cells treated with siRNA targeting hSLC2A1
(hGLUT1 kd).
Glucose Transporter FRET Screen
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assay can identify glucose transporter-specific inhibitors and fur-
ther distinguish compounds with high selectivity for their target
over its orthologues or isoforms.
DISCUSSION
We describe here the development of a novel assay system adapt-
able to high-throughput screening for smallmolecules that inhibit
glucose uptake. The ability to identify compounds with selectivity
for the malarial glucose transporter PfHT over human GLUT
transporters provides a powerful new means to identify safe and
effective antimalarial agents. Our results show high reproducibil-
ity, with a CV of 2% and good separation of hits from back-
ground, with a Z= factor of0.8, indicative of a high-quality assay
for high-throughput screening (22). Additionally, by not requir-
ing radioactive labels, this assay increases throughput and ease of
use with substantially reduced cost. This is especially important in
the field of infectious diseases affecting people in the developing
world (24). The assay employs cells that genetically encode the glu-
cose transporter and a glucose sensor utilizing a direct fluorescent
readout. This eliminates the need for time-consuming protein puri-
ficationstepsandexpensive radiolabeledorfluorescently labeled sub-
strates. Every step in our protocol was successfully tested in a fully
automated setup in order to test the true scalability to high through-
put. Our initial screen of a 400-compound library resulted in four
verifiedhits.Although the rateof false-positive compounds identified
after the initial round of screening is significantly lower than in a
previously reportedPfHTinhibitor assay (15), further improvements
can bemade by selecting a higher threshold of FRET ratio reduction,
especially when screening a larger library or using different detection
methods like fluorescence lifetime (25, 26). The hits identified in this
screen include three compounds (MMV009085, MMV020548, and
MMV665879) that were previously identified and characterized
by Ortiz et al. (15) to selectively inhibit glucose uptake, but not
proline transport, in PfHT-overexpressing Leishmania mexicana.
However, the L. mexicana assay system showed noncorrelated re-
sults for the IC50 of compound MMV009085 (IC50 of 0.99 M in
themalaria parasite growth assay but 0.051M in the L. mexicana
PfHT overexpression assay). This 20-fold difference in potency by
the two assays indicates that in the cross-expression system (PfHT
in the Leishmania parasite) MMV009085 might have an alterna-
tive target, originating from L. mexicana. In our screen, reduc-
tion in FRET ratio correlated with inhibitory potency of the com-
pound in the freed-parasite glucose uptake assay (R2  0.83,
excluding outlier MMV000326), with the most potent inhibitor,
MMV009085, showing the strongest decrease in FRET ratio.
The quality of hits in drug discovery projects is crucial in im-
proving the odds of developing a successful candidate for clinical
application, especially as downstream investments into the hits
that are selected for lead development are significant in terms of
both funding and time (24). Therefore, target-based screens have
advantages over phenotypic screens, as they allow lead identifica-
tion and optimization that are directed toward the malarial target
protein versus human orthologues. We adapted our assay system
to include counterscreening of PfHT-specific hits against human
glucose transporters. The facilitative glucose transporters GLUT1
to -4 are fundamentally important for human glucose homeostasis,
as they are primary glucose transporters inmost tissues (27). PfHT
and the human transporters share a major facilitator superfamily
(MFS) fold and show a sequence similarity of close to 50%. The sig-
nificance of the human GLUTs and their close homology to thema-
larial glucose transportermake it crucial, but potentially challenging,
to identify drugs with high parasite orthologue selectivity. By replac-
ing PfHT with human GLUTs, our HEK293 cell-based assay system
successfully distinguished PfHT-specific from orthologue-nonspe-
cific inhibitors and identified a compound that showed a 19- to
250-fold high selectivity for PfHT over the human GLUTs.
An additional advantage of target-directed screening is the op-
portunity for structure-based rational drug design to aid in lead
compound optimization, particularly with respect to selectivity
for PfHT over human GLUTs. For the mammalian glucose trans-
porters, recent progress has beenmade in solving the crystal struc-
tures of several isoforms in both inward and outward conforma-
tions (28–30). Furthermore, our prior work has provided
evidence for the binding pocket that mediates transporter inhibi-
tion by HIV protease inhibitors (12, 20, 31). This has been used to
model lopinavir binding to amodel of PfHT (12). Taken together,
these data provide a framework for iterative structure-activity
analysis of compounds identified via our newly developed high-
throughput screening assay.
In addition to selecting orthologue-specific PfHT inhibitors,
the GLUT-expressing FLIP cell lines can be used to identify
FIG 6 Specificity of hit compounds for PfHT over human orthologues. (a) Uptake of [3H]2-DOG by HEK293 cells overexpressing hGLUT1 to hGLUT4 in the
presence of hit compounds at their IC50 for PfHT (Table 2). (b) Uptake of [
3H]2-DOG by HEK293 cells overexpressing PfHT or hGLUT1 to hGLUT4 at
increasing concentrations of compound MMV009085. Uptake data are expressed as means SEMs (n 3). IC50s were calculated using nonlinear regression
analysis.
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GLUT-specific inhibitors with isoform selectivity with applica-
tions beyond antimalarial therapy. Several types of tumors have
been shown to overexpress specific GLUT isoforms that mediate
the transport of high levels of glucose to malignant cells that have
undergone metabolic rearrangement and primarily metabolize
glucose through aerobic glycolysis (known as theWarburg effect)
(32, 33). Many cancer cells express transporter isoforms that are
not found in these tissues under nonmalignant conditions.
Among the class 1 facilitative glucose transporters, GLUT1 ismost
abundantly expressed in breast, brain, lung, colorectal, and blad-
der cancers (34). Inhibition of GLUT1 has already been shown to
exert antineoplastic effects both in vitro and in vivo (35, 36), mak-
ing it a promising target for cancer therapy. Expression of the
glucose transporters GLUT2, GLUT3, and GLUT4 is also upregu-
lated in various tumors, among them several types that are diffi-
cult to treat and are associated with low survival rates, like lung,
pancreatic, and liver tumors (32, 34, 37). Our cell-based, target-
specific screen is designed to be easily adaptable to mediate glu-
cose transport through selectively expressed transporter isoforms.
This versatility combined with a robust, easily detectable readout
significantly increases the feasibility of screening large compound
libraries to identify isoform-specific GLUT inhibitors that can be
further developed into drugs for either stand-alone or adjunct
cancer therapy.
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